The LYN Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the LYN gene in the AGS human gastric adenocarcinoma epithelial cell line. This product provides a genetically defined model for interrogating LYN function in the context of gastric adenocarcinoma, facilitating pathway analysis and therapeutic target validation. The polyclonal configuration ensures a heterogeneous knockout population suitable for bulk functional assays without clonal selection artifacts.
The AGS host cell line is derived from a gastric adenocarcinoma of a Caucasian female patient and is widely utilized as an in vitro model for gastric cancer research. These epithelial cells retain key molecular features of gastric adenocarcinoma, including responsiveness to growth factors and integrin-mediated adhesion, and are frequently used in the development of targeted therapies and drug resistance studies.
LYN encodes a non-receptor tyrosine kinase of the Src family that functions as a pivotal mediator of signal transduction downstream of cell surface receptors. In AGS cells, LYN is activated by integrin receptors, epidermal growth factor receptor (EGFR), c-Met, and cytokine receptors, and subsequently phosphorylates downstream targets such as SYK, FAK, and STAT3. It engages adaptor proteins including GRB2, SHC1, and GAB2, and interacts with CBL, CD19, and the phosphatase SHP-1. Through these interactions, LYN orchestrates the activation of the PI3K/AKT and MAPK/ERK cascades, thereby regulating cellular proliferation, migration, differentiation, and survival.
Disruption of LYN in the AGS background abrogates key oncogenic signals driven by integrin and growth factor receptor pathways. The knockout cells exhibit impaired PI3K/AKT and MAPK/ERK phosphorylation, leading to reduced cell migration, invasion, and proliferation. This model is highly relevant for investigating LYN??s contribution to gastric adenocarcinoma progression and for exploring mechanisms of resistance to Src-family kinase inhibitors. Additionally, it serves as a platform to study integrin signaling dynamics and crosstalk with other receptor tyrosine kinases, and to examine the consequent alterations in downstream transcriptional programs, including NF-??B-mediated gene expression.
Researchers can employ the LYN Knockout AGS Polyclonal Cells for a wide range of experimental applications, including confirmation of LYN protein and mRNA ablation by western blotting and RT-qPCR, phospho-signaling analysis (e.g., p-AKT, p-ERK) to assess pathway activity, and functional assays such as wound healing, transwell migration, and MTT or BrdU proliferation assays. The polyclonal nature of these knockout cells provides a population-level loss of LYN function, which is particularly useful for studying heterogeneous responses in drug sensitivity and signaling assays. Flow cytometry enables cell cycle profiling, while drug sensitivity screens with Src inhibitors like dasatinib facilitate tyrosine kinase inhibitor studies. These cells are also suited for integrin signaling research and investigations into drug resistance mechanisms. For further information, please contact Ascent Research.
